Trial Profile
A Phase II Evaluation of Pazopanib in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Leiomyosarcoma
- Focus Adverse reactions; Therapeutic Use
- 17 Nov 2015 Status changed from not yet recruiting to withdrawn prior to enrolment.as reported by ClinicalTrials.gov record.
- 09 Mar 2015 New trial record